IP Library Granted Patent US 9,809,800
Granted Patent B2
US 9,809,800 · App. 14/646,115 · Granted Nov 7, 2017

Method for producing parvovirus having high infectivity titer

Inventor: Koichiro Yanagida (Tokyo, JP)
Assignee: ASAHI KASEI MEDICAL CO., LTD.
C12N7/00C12N2750/14351
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,809,800
App. No.
14/646,115
Granted
Nov 7, 2017
Kind
B2
Abstract

A method for stably and easily producing a parvovirus having a high infectivity titer is provided. The problem is solved by a method for producing a parvovirus having an infectivity titer as high as 10 8 TCID 50 /mL or more in a culture supernatant, comprising the steps of inoculating a seed virus of the parvovirus into a culture substrate comprising host cells having a cell density of 1/500 to 1/20 of the cell density of the host cells confluently grown and a medium at a multiplicity of infection of 0.0001 to 0.1, culturing for a period of 5 to 11 times the doubling time of the host cells, and recovering a culture supernatant.

Claims (19)

1. A method for producing a parvovirus in a culture supernatant by culturing host cells and a seed virus of the parvovirus in a culture substrate, comprising:

(a) calculating: a doubling time of the host cells during the log growth phase in the culturing; and a cell density of the host cells confluently grown in the culturing;

(b) inoculating the seed virus of the parvovirus into the culture substrate comprising a medium and the host cells having a cell density of 1/500 to 1/20 of the cell density of the host cells confluently grown, calculated in (a), to give a multiplicity of infection (MOI) of 0.0001 to 0.1;

(c) culturing the culture comprising the medium and the host cells having a cell density of 1/500 to 1/20 of the cell density of the host cells confluently grown and the inoculated parvovirus obtained in (b) for a period of 5 to 11 times the doubling time calculated in (a); and

(d) recovering a culture supernatant comprising the parvovirus, obtained by the culturing (c).

2. The method according to claim 1 , wherein the host cell is an adhesion-dependent cell.

3. The method according to claim 1 , wherein the host cell is a cell susceptible to the parvovirus.

4. The method according to claim 1 , wherein the parvovirus is porcine parvovirus (PPV), canine parvovirus (CPV), minute virus of mice (MVM), rat virus (RV), H-1 virus (H-1), feline parvovirus (FPV), goose parvovirus (GPV), or bovine parvovirus (BPV).

5. The method according to claim 1 , wherein in (b), the seed virus of the parvovirus is inoculated into the culture substrate comprising a medium and the host cells having a cell density of 1/300 to 1/30 of the cell density of the host cells confluently grown, calculated in (a), to give a multiplicity of infection (MOI) of 0.0001 to 0.1.

6. The method according to claim 1 , wherein in (b), the seed virus of the parvovirus is inoculated into the culture substrate comprising a medium and the host cells having a cell density of 1/200 to 1/40 of the cell density of the host cells confluently grown, calculated in (a), to give a multiplicity of infection (MOI) of 0.0001 to 0.1.

7. The method according to claim 1 , wherein the multiplicity of infection (MOI) is 0.001 to 0.03.

8. The method according to claim 7 , wherein the multiplicity of infection (MOI) is 0.003 to 0.01.

9. The method according to claim 1 , wherein when the medium is a serum medium, (c) comprises replacing the serum medium with a serum-free medium.

10. The method for producing a parvovirus according to claim 1 , wherein in (c), the culture is cultured for a period of 6 to 9 times the doubling time calculated in (a).

11. The method for producing a parvovirus according to claim 10 , wherein in (c), the culture is cultured for a period of 7 to 8 times the doubling time calculated in (a).

12. The method for producing a parvovirus according to claim 1 , wherein in (c), the culture is cultured at a temperature of from 33° C. to 39° C.

13. The method for producing a parvovirus according to claim 1 , wherein in (c), the host cells and the virus grow concurrently.

14. The method according to claim 1 , wherein (d) comprises removing free host cells and host cell debris contained in the culture supernatant.

15. The method according to claim 14 , wherein the removing is performed using filtration with a membrane having a pore diameter of 0.2 μm to 0.45 μm.

Assignments (3)
NUNC PRO TUNC ASSIGNMENT Recorded Oct 23, 2025
From: ASAHI KASEI MEDICAL CO., LTD.
To: ASAHI KASEI LIFE SCIENCE CORPORATION
Reel/Frame 072650/0301 →
CHANGE OF ADDRESS Recorded Oct 23, 2025
From: ASAHI KASEI MEDICAL CO., LTD.
To: ASAHI KASEI MEDICAL CO., LTD.
Reel/Frame 073191/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2015
From: YANAGIDA, KOICHIRO
To: ASAHI KASEI MEDICAL CO., LTD.
Reel/Frame 036010/0034 →
Priority Claims (1)
JP 2012-256801 · Nov 22, 2012 · national
Continuity (1)
Related Publication 20150299668A1 · Oct 22, 2015